A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Betaxon Side Effects, and Drug Interactions - Levobetaxolol
Betaxon Side Effects, and Drug Interactions - Levobetaxolol
SIDE EFFECTS
Ocular: In clinical trials, the most frequent event associated
with the use of BETAXON™ Ophthalmic Suspension 0.5% has been transient ocular
discomfort upon instillation (11%). Transient blurred vision has been reported
in approximately 2% of patients. Other ocular events have been reported in less
than 2% of patients and include: cataracts, and vitreous disorders. All other
ocular events occurred one time at an incidence of less than 0.2%.
Systemic: Systemic reactions following administration of
BETAXON™ Ophthalmic Suspension 0.5% and other topical ocular formulations of
betaxolol have been at an incidence of less than 2%.
These include:
Cardiovascular: Bradycardia, heart block, hypertension,
hypotension, tachycardia, and vascular anomaly.
Central Nervous System: Anxiety, dizziness, hypertonia,
and vertigo.
Digestive: Constipation and dyspepsia.
Endocrine: Diabetes and hypothyroidism.
Metabolic and Nutritional Disorders: Gout, hypercholesteremia,
and hyperlipidemia.
Musculoskelatal: Arthritis and tendonitis.
Pulmonary: Pulmonary distress characterized by bronchitis,
dyspnea, pharyngitis, pneumonia, rhinitis, and sinusitis.
Skin and Appendages: Alopecia, dermatitis, and psoriasis.
Special Senses: Ear pain, otitis media, taste perversion,
and tinnitus.
Urogenital: Breast abscess and cystitis.
Other: Accidental injury, headache, and infection.
DRUG INTERACTIONS
Patients who are receiving a beta-adrenergic blocking agent orally and BETAXON™ Ophthalmic Suspension should be observed
for a potential additive effect either on the intraocular pressure or on the
known systemic effects of beta blockade. Close observation of the patient is
recommended when a beta blocker is administered to patients receiving catecholamine-depleting
drugs such as reserpine, because of possible additive effects and the production
of hypotension and/or bradycardia. Levobetaxolol is an adrenergic blocking agent;
therefore, caution should be exercised in patients using concomitant adrenergic
psychotropic drugs.
Risk from anaphylactic reaction: While taking beta-blockers,
patients with a history of atopy or a history of severe anaphylactic reaction
to a variety of allergens may be more reactive to repeated accidental, diagnostic,
or therapeutic challenge with such allergens. Such patients may be unresponsive
to the usual doses of epinephrine used to treat anaphylactic reactions.
Ocular: In patients with angle-closure glaucoma, the immediate
treatment objective is to reopen the angle by constriction of the pupil with
a miotic agent. Racemic betaxolol has little or no effect on the pupil. It is
expected that levobetaxolol will also have little or no effect on the pupil.
When BETAXON™ Ophthalmic Suspension is used to reduce elevated intraocular pressure
in angle-closure glaucoma, it should be used with a miotic and not alone.
top
